학술논문
The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD
Document Type
Article
Author
Markey, Kate A.; Schluter, Jonas; Gomes, Antonio L. C.; Littmann, Eric R.; Pickard, Amanda J.; Taylor, Bradford P.; Giardina, Paul A.; Weber, Daniela; Dai, Anqi; Docampo, Melissa D.; Armijo, Gabriel K.; Slingerland, Ann E.; Slingerland, John B.; Nichols, Katherine B.; Brereton, Daniel G.; Clurman, Annelie G.; Ramos, Ruben J.; Rao, Arka; Bush, Amy; Bohannon, Lauren; Covington, Megan; Lew, Meagan V.; Rizzieri, David A.; Chao, Nelson; Maloy, Molly; Cho, Christina; Politikos, Ioannis; Giralt, Sergio; Taur, Ying; Pamer, Eric G.; Holler, Ernst; Perales, Miguel-Angel; Ponce, Doris M.; Devlin, Sean M.; Xavier, Joao; Sung, Anthony D.; Peled, Jonathan U.; Cross, Justin R.; van den Brink, Marcel R. M.
Source
Blood; July 2020, Vol. 136 Issue: 1 p130-136, 7p
Subject
Language
ISSN
00064971; 15280020
Abstract
Studies of the relationship between the gastrointestinal microbiota and outcomes in allogeneic hematopoietic stem cell transplantation (allo-HCT) have thus far largely focused on early complications, predominantly infection and acute graft-versus-host disease (GVHD). We examined the potential relationship of the microbiome with chronic GVHD (cGVHD) by analyzing stool and plasma samples collected late after allo-HCT using a case-control study design. We found lower circulating concentrations of the microbe-derived short-chain fatty acids (SCFAs) propionate and butyrate in day 100 plasma samples from patients who developed cGVHD, compared with those who remained free of this complication, in the initial case-control cohort of transplant patients and in a further cross-sectional cohort from an independent transplant center. An additional cross-sectional patient cohort from a third transplant center was analyzed; however, serum (rather than plasma) was available, and the differences in SCFAs observed in the plasma samples were not recapitulated. In sum, our findings from the primary case-control cohort and 1 of 2 cross-sectional cohorts explored suggest that the gastrointestinal microbiome may exert immunomodulatory effects in allo-HCT patients at least in part due to control of systemic concentrations of microbe-derived SCFAs.